The principal objective of the proposed research is to elucidate the mechanisms and regulation of biosynthesis, storage, and release of vascular endothelium-derived nitric oxide (ENDO) from intact artery and vein and isolated endothelial cells. The central hypothesis is that NO is formed and released endogenously from such cells and elicits important pharmacological and physiological actions. Earlier studies from this laboratory indicated that authentic NO causes potent and marked but transient vascular smooth muscle relation, inhibition of platelet aggregation, increase cyclic GMP accumulation in such cells, heme-dependent activation of soluble guanylate cyclase, all of which can be antagonized by hemoproteins of methylene blue. Recent studies from this laboratory reveled independently the one endothelium-derived relaxing factor (EDRF) from artery and vein is NO or an unstable nitroso compound that spontaneously liberates NO. Therefore, the proposed studies are designed to characterize further the biochemistry and pharmacology of EDNO, as well as the formation of NO by activated the macrophages, neutrophils, and other tissues.
FIVE specific aims are proposed to achieve the objective: 1) to elucidate the mechanism(s) by which ENDO is synthesized and the factors influencing EDNO formation; 2) to ascertain whether EDRF is pure NO or a mixture of NO plus a labile nitroso precursor; 3) to characterize the biochemical pathway of NO formation from L-arginine in vascular endothelial cells and other tissues; 4) to ascertain whether inorganic nitrite (NO2) is the major biotransformation product of ENDO in vascular tissue; 5) to ascertain whether vascular endothelial cell cyclic GMP plays any role in the regulation of ENDO formation and/or release. These objectives and aims represent a continuing long-term effort to elucidate the pharmacology of NO as well as the biological factors that influence and regulate vascular smooth muscle tone. New information on the possible source, formation, release, and actions of endogenous NO should lead to a better understanding of the etiology and therapy of certain cardiovascular disorder including essential hypertension, vasospasm, stroke.
|Garban, Hermes J; Marquez-Garban, Diana C; Pietras, Richard J et al. (2005) Rapid nitric oxide-mediated S-nitrosylation of estrogen receptor: regulation of estrogen-dependent gene transcription. Proc Natl Acad Sci U S A 102:2632-6|
|Garban, Hermes J; Buga, Georgette M; Ignarro, Louis J (2004) Estrogen receptor-mediated vascular responsiveness to nebivolol: a novel endothelium-related mechanism of therapeutic vasorelaxation. J Cardiovasc Pharmacol 43:638-44|
|Jacobs, Aaron T; Ignarro, Louis J (2003) Nuclear factor-kappa B and mitogen-activated protein kinases mediate nitric oxide-enhanced transcriptional expression of interferon-beta. J Biol Chem 278:8018-27|
|Jacobs, Aaron T; Ignarro, Louis J (2003) Cell density-enhanced expression of inducible nitric oxide synthase in murine macrophages mediated by interferon-beta. Nitric Oxide 8:222-30|
|Ignarro, Louis J; Byrns, Russell E; Trinh, Kim et al. (2002) Nebivolol: a selective beta(1)-adrenergic receptor antagonist that relaxes vascular smooth muscle by nitric oxide- and cyclic GMP-dependent mechanisms. Nitric Oxide 7:75-82|
|Bauer, P M; Buga, G M; Fukuto, J M et al. (2001) Nitric oxide inhibits ornithine decarboxylase via S-nitrosylation of cysteine 360 in the active site of the enzyme. J Biol Chem 276:34458-64|
|Bauer, P M; Buga, G M; Ignarro, L J (2001) Role of p42/p44 mitogen-activated-protein kinase and p21waf1/cip1 in the regulation of vascular smooth muscle cell proliferation by nitric oxide. Proc Natl Acad Sci U S A 98:12802-7|
|Jacobs, A T; Ignarro, L J (2001) Lipopolysaccharide-induced expression of interferon-beta mediates the timing of inducible nitric-oxide synthase induction in RAW 264.7 macrophages. J Biol Chem 276:47950-7|
|Wei, L H; Morris Jr, S M; Cederbaum, S D et al. (2000) Induction of arginase II in human Caco-2 tumor cells by cyclic AMP. Arch Biochem Biophys 374:255-60|
|Wei, L H; Jacobs, A T; Morris Jr, S M et al. (2000) IL-4 and IL-13 upregulate arginase I expression by cAMP and JAK/STAT6 pathways in vascular smooth muscle cells. Am J Physiol Cell Physiol 279:C248-56|
Showing the most recent 10 out of 55 publications